Vaxcyte Historical Income Statement
| PCVX Stock | USD 91.70 3.16 3.57% |
Historical analysis of Vaxcyte income statement accounts such as Depreciation And Amortization of 4 M, Total Revenue of 0.0, Other Operating Expenses of 491.4 M or Research Development of 349 M can show how well Vaxcyte performed in making a profits. Evaluating Vaxcyte income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Vaxcyte's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Vaxcyte latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Vaxcyte is a good buy for the upcoming year.
Vaxcyte |
About Vaxcyte Income Statement Analysis
Vaxcyte Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Vaxcyte shareholders. The income statement also shows Vaxcyte investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Vaxcyte Income Statement Chart
Add Fundamental
Net Income Applicable To Common Shares
The net income that remains after preferred dividends have been deducted, available to common shareholders.Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Vaxcyte. It is also known as Vaxcyte overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from Vaxcyte's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Vaxcyte current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Vaxcyte. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. For more information on how to buy Vaxcyte Stock please use our How to Invest in Vaxcyte guide.At this time, Vaxcyte's Interest Income is fairly stable compared to the past year. Selling General Administrative is likely to rise to about 63.7 M in 2024, whereas Interest Expense is likely to drop 0.00 in 2024.
| 2021 | 2022 | 2023 | 2024 (projected) | Depreciation And Amortization | 1.8M | 9.2M | 3.2M | 4.0M | Net Interest Income | 337K | 8.4M | 62.9M | 66.1M |
Vaxcyte income statement Correlations
Click cells to compare fundamentals
Vaxcyte Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Vaxcyte income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Interest Income | 632K | 244K | 344K | 8.4M | 62.9M | 66.1M | |
| Selling General Administrative | 8.5M | 16.0M | 25.3M | 39.8M | 60.7M | 63.7M | |
| Operating Income | (54.2M) | (89.6M) | (103.7M) | (232.3M) | (468.0M) | (444.6M) | |
| Ebit | (54.2M) | (89.2M) | (100.1M) | (223.5M) | (468.0M) | (444.6M) | |
| Income Before Tax | (50.3M) | (89.2M) | (100.1M) | (223.5M) | (402.3M) | (382.2M) | |
| Net Income Applicable To Common Shares | (50.3M) | (89.2M) | (100.1M) | (223.5M) | (201.1M) | (191.1M) | |
| Net Income | (53.5M) | (87.8M) | (100.1M) | (239.6M) | (402.3M) | (382.2M) | |
| Net Interest Income | 592K | 237K | 337K | 8.4M | 62.9M | 66.1M | |
| Depreciation And Amortization | 5.3M | 1.4M | 1.8M | 9.2M | 3.2M | 4.0M | |
| Other Operating Expenses | 53.9M | 87.1M | 102.1M | 207.3M | 468.0M | 491.4M | |
| Net Income From Continuing Ops | (50.3M) | (89.2M) | (100.1M) | (223.5M) | (402.3M) | (382.2M) | |
| Research Development | 45.6M | 73.6M | 78.4M | 169.5M | 332.3M | 349.0M | |
| Ebitda | (48.9M) | (87.8M) | (98.3M) | (214.3M) | (464.9M) | (441.6M) | |
| Total Operating Expenses | 53.9M | 87.1M | 102.1M | 207.3M | 468.0M | 491.4M | |
| Reconciled Depreciation | 1.2M | 1.4M | 3.5M | 9.2M | 10.2M | 10.7M | |
| Total Other Income Expense Net | 3.9M | 364K | 3.6M | 8.8M | 65.8M | 69.1M | |
| Income Tax Expense | 3.2M | (1.4M) | 7K | 16.2M | (402.3M) | (382.2M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Vaxcyte Stock Analysis
When running Vaxcyte's price analysis, check to measure Vaxcyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxcyte is operating at the current time. Most of Vaxcyte's value examination focuses on studying past and present price action to predict the probability of Vaxcyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxcyte's price. Additionally, you may evaluate how the addition of Vaxcyte to your portfolios can decrease your overall portfolio volatility.